Clinical Trials
Kelun-Biotech’s Sac-TMT–Keytruda Combination Outperforms Standard First-Line Therapy in Phase III Lung Cancer Trial
As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-L...
July 16, 2026 | News
Q32 Bio Reports Positive Phase 2a Results for Bempikibart in Severe Alopecia Areata, Plans Pivotal Programme
-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline o...
July 15, 2026 | News
Delonix Bioworks Doses First Participant in China Phase 1 Trial of Next-Generation MenB Vaccine DX-104
Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, announced that the first participant has bee...
July 15, 2026 | News
BioArctic and Eisai Secure FDA Approval for At-Home Leqembi Injection to Treat Early Alzheimer's Disease
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced that the US Food and Drug Administration (FDA) has approved a supplement...
July 15, 2026 | News
Leads Biolabs' Opamtistomig Receives China's Priority Review for Advanced Neuroendocrine Cancer
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Op...
July 14, 2026 | News
Pfizer and Astellas Expand FDA Approval of PADCEV Plus Keytruda Across All Muscle-Invasive Bladder Cancer Patients
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that the U.S. Food and Dru...
July 14, 2026 | News
China Grants Priority Review to Leads Biolabs' Opamtistomig for Advanced Neuroendocrine Cancer
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the biologics license application (BLA) for Op...
July 13, 2026 | News
ACHP Launches Patient Advisory Council to Put Chronic Disease Voices at the Heart of Research
The Alliance of Community Health Plans (ACHP) is amplifying patients' voices on chronic disease research via its newly launched Patient Advisory Council. T...
July 13, 2026 | News
Lynk Pharmaceuticals Doses First Patient in Phase II Trial of Novel Vitiligo Therapy
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...
July 10, 2026 | News
Insilico Medicine Advances AI-Discovered IPF Drug Rentosertib into Phase III Trial
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-...
July 09, 2026 | News
Singapore Updates Wegovy Label to Include Higher-Dose Semaglutide Data Showing Up to 25% Weight Loss
Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 2...
July 09, 2026 | News
Europe Approves TEPKINLY Combination as First Bispecific-Based Second-Line Therapy for Follicular Lymphoma
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Euro...
July 08, 2026 | News
J-Pharma Advances First-in-Class LAT1 Inhibitor Nanvuranlat into Global Phase 3 Trial for Biliary Tract Cancer
Pharma Co., Ltd., a clinical-stage biotechnology company focused on novel therapies targeting amino acid transporters, and Uniphar, a leading international...
July 08, 2026 | News
Arima Genomics Partners with Active Motif to Expand Global Access to Hi-C Research Portfolio
Agreement Part of Arima’s Long-Term Strategy to Focus on Core Diagnostic Platform and Tests Arima Genomics, Inc., a cancer diagnostics com...
July 07, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
